Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes ...
Autolus Therapeutics plc (NASDAQ: AUTL) is a London-headquartered, clinical-stage biopharmaceutical company focused on engineering and developing advanced autologous T-cell therapies for patients with cancer and, potentially, other immune-mediated diseases. The company’s core platform centers on cellular programming to generate targeted T-cell products designed to recognize specific disease antigens and deliver ...Autolus Therapeutics plc (NASDAQ: AUTL) is a London-headquartered, clinical-stage biopharmaceutical company focused on engineering and developing advanced autologous T-cell therapies for patients with cancer and, potentially, other immune-mediated diseases. The company’s core platform centers on cellular programming to generate targeted T-cell products designed to recognize specific disease antigens and deliver anti-tumor activity. This positioning places Autolus in the biotechnology sector with a specialized, highly technical product-development workflow that typically spans discovery, preclinical studies, and clinical trials through multiple phases.
A key part of Autolus’s public narrative is its expanding pipeline of programmed T-cell therapies. In the CD19 space, its lead program obecabtagene autoleucel (AUTO1) is described as being in Phase 1b/2 clinical testing for adult acute lymphoblastic leukemia (ALL). A related program, AUTO1/22, is also referenced as a Phase 1 study for pediatric patients with relapsed or refractory ALL. For solid and hematologic malignancies beyond CD19, Autolus is advancing other targeted constructs, including AUTO4, a programmed T-cell therapy intended to target TRBC1 for peripheral T-cell lymphoma. The company also reports progression of AUTO8 in Phase I clinical trials for multiple myeloma, while earlier development programs include AUTO6NG (preclinical) targeting GD2 for neuroblastoma and AUTO5 as an additional preclinical candidate.
From a “business and product” perspective, Autolus does not manufacture conventional pharmaceuticals at scale; instead, it develops individualized or semi-individualized cellular therapies that require specialized manufacturing and quality controls, often supported by contract and/or internal capabilities. This drives a cost structure dominated by R&D spending, clinical trial execution, regulatory work, and the build-out of the operational pathway necessary to support clinical (and potentially commercial) administration. Provided materials also indicate the company anticipates a commercial launch in the United Kingdom in the second half of 2025, highlighting the possibility of transitioning from development into commercialization activities, which would bring additional expenses such as market access, supply chain readiness, and post-approval lifecycle work.
Financially, the company’s publicly available metrics reflect typical early-to-mid clinical-stage biotech economics: substantial investment intensity, negative profitability indicators in trailing measurements, and heavy reliance on capital markets and financing structures rather than near-term product revenue. In terms of key people, Christian Martin Itin is the Chief Executive Officer, and the company’s leadership history includes founder Dr. Martin Pule (with the company described as spun out from University College London in 2014). With a workforce reported around 752 full-time employees, Autolus operates at a scale consistent with organizations managing multiple clinical programs and complex scientific/manufacturing operations. Overall, Autolus’s “wish list” from a stakeholder viewpoint is straightforward: generate durable clinical efficacy across targeted indications, secure regulatory approvals, and build operational readiness for manufacturing, distribution, and patient access as candidates mature from early trials toward later development and potential commercialization.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$75.6M
+646.7%
+74.3%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-288.2M
-30.6%
+45.4%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
-27.8%
+97.8%
+777.1%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-372.4%
+84.4%
+57.7%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-381.4%
+82.5%
+68.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-310.7M
-28.9%
+61.8%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-411.2%
+82.7%
+78.1%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
197.4%
+1502.6%
+51.9%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
5.94x
-45.4%
-15.8%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
Operator: Good day, and thank you for standing by. Welcome to the Autolus Therapeutics Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Executive Director of Investor Relations, Amanda Cray. Please go ahead.
Amanda Cray: Thank you, Dede. Good morning and good afternoon, everyone, and thank you for joining us on today's call. With me are Chief Executive Officer, Dr. Christian Itin; and Chief Financial Officer, Rob Dolski. I'd like to remind you that during today's call, we will make statements related to our business that are forward-looking under federal securities laws and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to, statements regarding the status of ongoing commercial launch of AUCATZYL in the U.S. and U.K., Autolus' manufacturing, sales and marketing plans for AUCATZYL, the market potential for AUCATZYL and the status of clinical trials, development and/or regulatory time lines and market opportunities for obe-cel and our other product candidates. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect our views only as of today. We assume no obligation to update any such forward-looking statements. For a discussion of the material risks and uncertainties that could affect our actual results, please refer to the risks identified in today's press release and in our SEC filings, both available on the Investors section of our website. On Slide 3, you'll see the agenda for today's call. As usual, Christian will provide an overview of our operational highlights. Rob will then discuss the financial results, and Christian will conclude with upcoming milestones and closing remarks. We'll then take questions. With that, I'm happy to turn it over to Christian.
Christian Itin: Thanks, Amanda, and welcome, everybody, to our second quarter call. We're moving to Slide #4. We had a very positive second quarter with strong AUCATZYL sales growth in this -- in our second year of launch now. When we look at the AUCATZYL revenue in the second quarter, we're at $45.7 million, which is a substantial increase over the $26 million that we had in the first quarter. For the first half of the year, we reached $71.9 million, which is close to the full year number that we had for our first year of launch last year. We see that the positive experience that the physicians are having with the product in the centers that we're active in, which is also reflected in the data that was collected by the ROCCA consortium and the real-world database that was presented at the TANDEM meeting. It builds a very strong foundation for the adoption of the product, and I think the continued positive momentum that we're seeing in the market. We also …
